Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07465796

A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma

The goal of this clinical trial is to collect data on the use of the CIPHER System when used by a surgeon during brain tumor removal. The main questions it aims to answer are:

* To evaluate the safety of the CIPHER System when used during brain tumor surgery (Primary) * To evaluate the function of the electrodes under recording and stimulating conditions during surgery (Secondary) Participants will undergo standard-of-care surgery to remove their tumor. Just before the tumor is removed, the CIPHER System will be tested on the main tumor and the surrounding margin areas. Participants will be monitored during standard hospital visits occurring during the recovery period after surgery as well as two- and six-weeks after surgery.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Royal Melbourne Hospital, Department of Neurosurgery 4 East

Melbourne, Victoria, 3050, Australia

Location status: Recruiting

Location contact

Andrew Morokoff, MBBS PhD FRACS

CONTACT

[email protected]

+61 393 482 712

Andrew Morokoff, MBBS PhD FRACS

PRINCIPAL_INVESTIGATOR

About this study

Brain tumor resection surgery involves a balance between removing tumor and preserving healthy tissue. Current standard-of-care mapping tools use limited electrode configurations on rigid substrates to stimulate and record brain activity for identifying functional brain areas to avoid. A more flexible and high electrode-count tool to map the tumor characteristics based on spontaneous neural activity could strengthen surgical outcomes.

Emerging evidence also demonstrates that brain tumors, such as gliomas, are not biologically isolated but instead integrate functionally into neural circuits. Electrical stimulation-based strategies could provide novel treatment modalities that target the neural-tumour interactions and improve patient outcomes.

This clinical investigation is a First-in-Human exploratory study of the CIPHER System, including a novel highly flexible, electrode-dense thin-film cortical probe developed for neurophysiological mapping and stimulation during brain tumour resection surgery. The study is designed to evaluate the safety, basic performance, and handling characteristics of the CIPHER System during short-duration intraoperative use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed supratentorial glioma requiring resection
  • Glioma mass reaches or close to cortical surface
  • Adults aged 18-75
  • Planned for open craniotomy under Total Intravenous Anesthesia (TIVA)
  • Patient able to provide informed consent
  • Performance status: Eastern Cooperative Oncology Group (ECOG) scale 0-2

Exclusion criteria

  • Prior craniotomy at the same anatomical location
  • Plan for awake craniotomy
  • Any history of seizures prior to craniotomy
  • Any history of coagulopathy or coagulation disorders
  • Pregnant status during craniotomy

Treatment and study plan

Electrocorticography for neural recording

Device

Electrocorticography probe placed on the brain surface for neural recording

Electrocorticography for neural recording and electrical stimulation

Device

Electrocorticography probe placed on the brain surface for neural recording and electrical stimulation

Primary outcomes

  1. Incidence of all device/procedure-related adverse events (safety and tolerability) relevant to the intended use of the study device

    Time frame: From enrollment to the end of postoperative six-week follow-up visit

    Monitoring of all device/procedure-related adverse events including, but not limited to, device-related postoperative observations for persistent seizures or status epilepticus

Secondary outcomes

  1. Presence or absence of spontaneous neural activity on recording electrodes

    Time frame: At enrollment

    Presence or absence of spontaneous cortical signals on each electrode within the array

  2. Signal-to-noise ratio of recorded signals

    Time frame: At enrollment

    Signal-to-noise ratio of recorded signals on each recording electrode

  3. Evaluate local field potential neural activity before and after stimulation

    Time frame: At enrollment

    Preliminary comparison of neural power spectra of local field potentials before and after stimulation

  4. Incidence and characterization of device deficiencies during intraoperative use

    Time frame: At enrollment

    Evaluation of the operating surgeon's responses to a study specific questionnaire including free text description of deficiency, categorization of the type of deficiency as well as outcomes and potential outcomes of deficiencies.

Study contacts

Contact information is provided by the study sponsor or research team.

Andrew Morokoff, MBBS PhD FRACS

CONTACT

[email protected]

+61 393 482 712

Sponsors and collaborators

Lead sponsor

Coherence Neuro Australia Pty Limited

Industry

Collaborators

  • Royal Melbourne Hospital, Australia

Registry information

Acronym: CIPHER

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 12, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.